Despite the current state of the literature, we cannot differentiate independent effects of obesity, insulin resistance or clinical T2DM on GLO1 protein expression or enzymatic activity; nor can it be determined if reductions in GLO1 are causative or a consequence of metabolic pathologies. Here, GLO1 is linked to obesity due to melanocortin 4 receptor deficiency.